Aspiriant LLC lowered its position in VanEck Biotech ETF (NASDAQ:BBH – Free Report) by 40.1% in the first quarter, Holdings Channel.com reports. The institutional investor owned 4,408 shares of the company’s stock after selling 2,955 shares during the period. Aspiriant LLC’s holdings in VanEck Biotech ETF were worth $733,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the company. CIBC Private Wealth Group LLC acquired a new position in VanEck Biotech ETF in the 4th quarter worth $572,000. Condor Capital Management acquired a new position in VanEck Biotech ETF in the 4th quarter worth $800,000. Focus Financial Network Inc. ADV acquired a new position in VanEck Biotech ETF in the 4th quarter worth $2,328,000. Pine Valley Investments Ltd Liability Co boosted its stake in VanEck Biotech ETF by 13.2% in the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 2,150 shares of the company’s stock worth $355,000 after purchasing an additional 250 shares during the period. Finally, Tidemark LLC acquired a new position in VanEck Biotech ETF in the 4th quarter worth $34,000. Institutional investors own 32.05% of the company’s stock.
VanEck Biotech ETF Stock Down 0.1 %
Shares of NASDAQ BBH opened at $170.01 on Friday. VanEck Biotech ETF has a 1-year low of $142.51 and a 1-year high of $173.49. The company has a fifty day moving average price of $164.85 and a 200 day moving average price of $164.35.
VanEck Biotech ETF Company Profile
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
See Also
- Five stocks we like better than VanEck Biotech ETF
- Compound Interest and Why It Matters When Investing
- Albemarle Stock: Strong Fundamentals vs. Lithium Volatility
- 3 Stocks to Consider Buying in October
- MongoDB Stock: Analysts Recommend Buying the Dip
- Stock Analyst Ratings and Canadian Analyst Ratings
- UniFirst Stock: Value-Building Sends a Signal to the Market
Want to see what other hedge funds are holding BBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Biotech ETF (NASDAQ:BBH – Free Report).
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
